Items Tagged ‘Waldenström’s macroglobulinemia’

February 24th, 2015

FDA Approves New Indication for Ibrutinib in Waldenström’s Macroglobulinemia

By

The US Food and Drug Administration (FDA) today expanded the approved use of Imbruvica® (ibrutinib) for patients with Waldenström’s macroglobulinemia, a rare type of B-cell lymphoma. Imbruvica® is the first therapy indicated specifically for Waldenström’s macroglobulinemia and previously received Breakthrough Therapy designation for this use. A type of non-Hodgkin lymphoma, Waldenström’s macroglobulinemia usually gets worse […]

View full entry

Tags: b-cell lymphoma, Breakthrough Therapy, ibrutinib, imbruvica, Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Waldenström’s macroglobulinemia